This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The authors, acting on behalf of the National Institute of Child Health and Human Development and Eli Lilly Company Growth Hormone Collaborative Group, performed a randomized, double-blind, placebo-controlled trial to determine the effect of growth hormone (GH) on final adult height when used in peripubertal children with idiopathic short stature. Subjects included 68 children (53 males) 9–16 years of age with marked idiopathic short stature, sexual maturation not greater than Tanner stage 2, and a bone age of 13 years or less in boys and 11 years or less in girls. Marked idiopathic short stature was defined by a height SD score (SDS) or predicted adult height SDS of −2.5 or less within the 12 months before study initiation, except before 1993 when a cutoff of −2.25 was used (6 such patients between −2.25 and −2.5 were included). Children were excluded if they had a chronic illness, known genetic syndrome, or had ever received growth or sex hormonal therapy, or were currently receiving medications with the potential to affect growth. Children were randomly assigned to receive …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
